Introduction {#Sec1}
============

Although surgery followed by radiotherapy and/or concurrent chemoradio- therapy has been the major treatment choice recommended by the NCCN guideline for treating locally advanced head and neck squamous cell carcinoma (HNSCC) for many years \[[@CR1]\], the outcome with this regimen is still limited by a low 5-year survival rate, which remains \< 40% \[[@CR2], [@CR3]\]. In recent years, several researches have suggested that preoperative radiotherapy and preoperative concurrent chemoradiotherapy may improve the overall survival (OS) compared to surgery alone in patients with head and neck cancer \[[@CR4]--[@CR6]\]. The advantages of preoperative radiotherapy or preoperative concurrent chemoradiotherapy for head and neck cancer include down-staging, increased resectability rate, etc. Further evidence from several phase 2 studies have shown that preoperative concurrent chemoradiotherapy provides excellent treatment outcomes by leading to a pathological complete response rate ranging from 35 to 61% and an increased 5-year OS rate of up to 70--81.5% \[[@CR5]--[@CR8]\].

Several authors have suggested that the pathological response to preoperative radiotherapy or chemoradiotherapy is a valuable prognostic factor for local control and OS \[[@CR9], [@CR10]\]. In one of our randomized phase 3 studies, we evaluated the role of adding concurrent cisplatin to preoperative radiotherapy in the treatment of locally advanced HNSCC \[[@CR11]\]. In this study, 222 eligible patients were randomly assigned to a preoperative radiotherapy group (*n* = 118) or a preoperative concurrent chemoradiotherapy group (*n* = 104). The results revealed that preoperative concurrent chemoradiotherapy led to a significantly improved distant metastasis-free survival (DMFS) compared to preoperative radiotherapy alone. According to the protocol, non-responders (defined by \< 80% reduction of the primary lesion after preoperative treatment), subsequently underwent resection of the primary lesion with or without neck dissection depending on the nodal status. In total, 72 non-responders (33.8%) were observed in this phase 3 study.

In the present study, we analyzed the relationships between pathological complete remission (pCR) and clinical outcomes in these 72 non-responder patients.

Materials and methods {#Sec2}
=====================

Patients {#Sec3}
--------

The details of the study design and data collection have been published in our previous study \[[@CR11]\]. In brief, from September 2002 to May 2012, a total of 222 HNSCC patients were enrolled in this phase 3 study, among which 104 patients were assigned to the preoperative concurrent chemoradiotherapy group and 118 patients were assigned to the preoperative radiotherapy group.

Treatment {#Sec4}
---------

All these patients received radiotherapy with either two-dimensional or intensity-modulated radiotherapy (IMRT). Patients assigned to the chemoradiotherapy group additionally received concurrent chemotherapy with 30 mg/m^2^ cisplatin weekly. The tumor response was assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI) and endoscopy examination at the end of the 5th week (50 Gy). Non-responders (defined as \< 80% reduction of the primary lesion volume) underwent resection of the primary tumor and modified neck dissection within 4--6 weeks after the completion of preoperative treatment. Seventy-two patients were non-responders, including 35 patients in the preoperative radiotherapy group and 37 patients in the chemoradiotherapy group.

Pathological response analysis {#Sec5}
------------------------------

The surgical samples of all clinical non-responders were assessed pathologically, and patients were classified according to the pathological response as the pCR group and non-pCR group, depending on whether residual tumor cells remained in the surgical sample or not.

Follow-up {#Sec6}
---------

After completion of the treatment plan, patients were followed up for a minimum of 5 years or until death, with a regular frequency: at 1 month, every 3 months for the first 2 years, every 6 months for the 2--5 years after treatment, and every year thereafter.

Statistical analysis {#Sec7}
--------------------

In our previous study, we revealed that in a subset of patients with primary tumors of the larynx-hypopharynx, preoperative chemoradiotherapy significantly improved the PFS and DMFS, and also provided a borderline benefit in OS in compared with preoperative radiotherapy. Therefore, in the current study, a sub-analysis comparing clinical outcomes in patients with larynx-hypopharynx primary tumors was performed.

Log-rank test was applied to compare the differences in baseline characteristics between pCR and non-pCR patients. The LC, OS, PFS and DMFS were calculated by the Kaplan--Meier method. The multivariate analysis were by Cox regressive analysis. All tests were two-sided and *p* \< 0.05 was considered statistically significant. All analyses were conducted using SPSS 21.0 software (IBM Corporation, Armonk, New York, U.S).

Results {#Sec8}
=======

Baseline characteristic between different pathological responses {#Sec9}
----------------------------------------------------------------

The total of 72 non-responders included 37 patients in the preoperative concurrent chemoradiotherapy group (*n* = 104) and 35 patients in the preoperative radiotherapy group (*n* = 118). Among these 72 non-responders, 25 patients (34.7%) achieved pCR, including 10 patients (10/37) in the chemoradiotherapy group and 15 patients (15/25) in the radiotherapy group (Table [1](#Tab1){ref-type="table"}). There were no significant differences between the pCR and non-pCR groups in terms of primary tumor site, tumor staging (T, N stage), grades of clinical group, and treatment technique (all *p* \> 0.05). Table 1Baseline characteristics of 72 patients with locally advanced head and neck squamous cell carcinoma according to whether they achieved pathological complete remission (pCR)CharacteristicpCR (*n* = 25)Non-pCR (*n* = 47)*p*-valuen%n%Gender Male2235.54064.50.735 Female330.0770.0Median age (years)5555Primary site Oral cavity430.8969.20.869 Oropharynx430.8969.2 Larynx/Hypopharynx1737.02963.0T stage  T1150.0150.00.218  T2763.6436.4  T3735.01365.0  T4a926.52573.5  T4b120.0480.0N stage  N0225.0675.00.266 N1110.0990.0 N21840.92659.1 N3440.0660.0Clinical group III114.3685.70.463 IVA922.53177.5 IVB533.31066.7Concurrent chemotherapy  Yes1027.02773.00.158  No1542.92057.1Radiotherapy technique 2D1429.83370.20.228  IMRT1144.01456.0*2D* Two dimensional, *IMRT* Intensity-modulated radiotherapy

Univariate analysis of prognostic impact of pCR for treatment outcomes {#Sec10}
----------------------------------------------------------------------

Over a median follow-up of 24 months (range, 3--122 months), the 5-year estimated LC, OS, PFS, and DMFS for pCR patients and non-pCR patients were 93.2% vs. 67.7% (*p* = 0.007), 83.3% vs. 39.7% (*p* = 0.0006), 76.1% vs. 44.0% (*p* = 0.003), and 90.4% vs. 56.3% (*p* = 0.005), respectively (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Differences in treatment outcomes between pCR and non-pCR patients among the whole cohort of patients: **a** local control, **b** overall survival, **c** progression-free survival, and **d** distant metastasis-free survival

There were 46 non-responders with larynx-hypopharynx primary tumors, 17 of whom achieved pCR of the primary lesion. The 5-year estimated LC, OS, PFS, and DMFS for these pCR and non-pCR patients were 100% vs. 81.4% (*p* = 0.068), 94.7% vs. 50.1% (*p* = 0.008), 81.9% vs. 51.2% (*p* = 0.03), and 94.1% vs. 61.1% (*p* = 0.02), respectively (Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Differences in treatment outcomes between the pCR and non-pCR patients who had primary tumors of the larynx-hypopharynx: **a** local control, **b** overall survival, **c** progression-free survival, and **d** distant metastasis-free survival

Multivariate analysis of prognostic impact of pCR for treatment outcomes {#Sec11}
------------------------------------------------------------------------

In multivariate analysis, pCR was an independent prognostic factors of LC(*p* = 0.002) (Table [2](#Tab2){ref-type="table"}) and OSwith statistically significant differences (p\<0.001) (Table [3](#Tab3){ref-type="table"}). And pCR also played an significant role in DMFS and PFS (Additional file [1](#MOESM1){ref-type="media"}: Table S1). In addition, the degree of pathological differentiation, primary lesion in hypopharynx/larynx and N stage were also independent prognostic factors for OS. Other factors such as gender, age, T stage, technology of radiation and chemotherapy were not independent prognostic factors for OS. Table 2Multivariate analysis for the local controlBSEpHR (95% CI)Gendermale vs female−.181.7020.7970.835 (0.211--3.304)Age≤55 vs \>551.263.7300.0843.535 (0.845--14.792)Primary sitehypopharyngeal carcinoma/laryngeal carcinoma vs other primary sites3.114.8470.00022.503 (4.279--118.346)Degree of pathological differentiationWell/modarate vs poor differentiaon / undifferentiation3.036.9140.00120.828 (3.476--124.821)T stageT4 vs T1--3−1.782.7570.0190.168 (0.038--0.743)N stageN0 vs N1--2 vs N32.445.8090.00311.527 (2.361--56.271)Technology of radiation2D vs IMRT.334.9710.7311.396 (0.208--9.359)ChemotherapyNo vs Yes−.182.5920.7580.833 (0.261--2.662)pCRYes vs No4.0041.2900.00254.839 (4.373--687.660) Table 3Multivariate analysis for the overall survivalBSEpHR (95% CI)Gendermale vs female−.816.5610.1460.442 (0.147--1.327)Age≤55 vs \>55.359.4250.3991.431 (0.622--3.294)Primary sitehypopharyngeal carcinoma/laryngeal carcinoma vs other primary sites1.024.4310.0182.783 (1.196--6.476)Degree of pathological differentiationWell/modarate vs poor differentiaon / undifferentiation1.833.5430.0016.254 (2.157--18.129)T stageT4 vs T1--3.406.4410.3571.501 (0.633--3.564)N stageN0 vs N1--2 vs N31.511.4890.0024.532 (1.737--11.824)Technology of radiation2D vs IMRT−.256.5720.6540.774 (0.252--2.376)ChemotherapyNo vs Yes−.596.4190.1550.551 (0.242--1.252)pCRYes vs No2.460.6940.00011.71 (3.003--45.663)

Discussion {#Sec12}
==========

The current analysis revealed that clinical outcomes including local control, OS, PFS, and DMFS were statistically better in patients with locally advanced HNSCC who achieved pCR than in those who did not. These results indicate that pCR could be used as a potential prognostic factor for patients with locally advanced HNSCC after preoperative irradiation.

Non-response after preoperative treatment was defined by a reduction in the primary lesion of less than 80% at the end of 50 Gy irradiation with or without chemotherapy as evaluated by CT/MRI and endoscopy examination. We identified 25 out of 72 (34.7%) patients who achieved pCR among those who were non-responders to preoperative treatment. In the study by Kirita et al. \[[@CR12]\], 48 patients with oral cavity cancer received cisplatin- or carboplatin-based preoperative concurrent chemoradiotherapy (RT 40 Gy), and the clinical CR and pCR rates were 60.4 and 50%, respectively. The lower pCR rate found in our study can primarily be attributed to the fact that only non-responding patients received surgical treatment in our study. In our phase 3 study, of the 222 patients enrolled, only 72 were non-responders based on imaging examination after 50 Gy irradiation with or without chemotherapy and underwent surgery. The other 150 patients who showed a good response received non-surgical therapy, and it is reasonable to expect that if they had been treated with surgery, the pCR rate would be higher in the 150 good responders than in the 72 non-responders.

Although planned preoperative concurrent chemoradiotherapy in head and neck cancer is not as popular as in esophageal cancer, rectal cancer, breast cancer, and non-small cell lung cancer, the relationship between pathological response and clinical outcome after preoperative radiotherapy has also been well studied. Friesland et al. \[[@CR13]\] reported that among 167 patients with tonsillar carcinoma treated by radiotherapy with or without surgery, 28% of patients received surgery for the primary site and/or neck dissection after radiotherapy, and the 5-year OS for patients with pCR was 43%, whereas that for patients with non-pCR was 9% (*p* \< 0.0001). The long-term prognostic value of achieving clinical CR, especially pCR in oral cancer was reported by Kirita et al \[[@CR12]\], who found that the 10-year PFS of patients with pCR was better than that of patients with extensive residual tumor (87.5% vs. 40%). In addition, patients who showed good histopathology responses had superior survival (*p* = 0.012). The same results were found in patients with tongue carcinoma \[[@CR14]\]; the PFS rates according to tumor regression rate were 33.3% for patients with less than 50% tumor regression, 66.7% for patients with 50--75% regression, 100% for patients with 75--100% regression, and 96.0% for patients with complete regression. The survival rate was statistically different between patients who achieved a regression rate of 75% or higher and those who did not (*p* \< 0.0001). Other authors also reported significant differences in treatment outcomes between good and poor responders, with 5-year survival rates of 68--84% versus 24--32% \[[@CR10], [@CR15]\].

Recently, preoperative concurrent chemoradiotherapy has been used increasingly more frequently in esophagogastric cancer, non-small cell lung cancer, rectal cancer, and breast cancer, and it was found that a good pathologic response to preoperative chemoradiotherapy correlates with better long-term survival in these cancers \[[@CR16]--[@CR25]\]. Even in resectable non-small cell lung cancer, the major pathological response was suggested to be a surrogate endpoint for survival in future neoadjuvant trials \[[@CR23]\]. Based on the results obtained in studies of esophagogastric cancer and rectal cancer, planned preoperative concurrent chemoradiotherapy may play an important role in the treatment of locally advanced head and neck cancer.

The relationship between clinical response and pathological response is still controversial. In our study, 25 (34.7%) clinical non-responders' achieved pCR for the primary lesion. For gastric-esophagus conjunction carcinoma, Cheedella et al. \[[@CR18]\] reported that the specificity of clinical CR for pCR is too low to be used for clinical decision-making regarding the delay or avoidance of surgery. The same finding was reported in rectal cancer treated with preoperative chemoradiotherapy \[[@CR26]\]. Accurately predicting pCR after preoperative treatment and thereby avoiding surgery is difficult. This issue has been the focus of many efforts in recent years, and functional imaging has been suggested to resolve this problem. Hatakenaka et al. \[[@CR27]\] found that pretreatment apparent diffusion coefficient (ADC) of the primary lesion correlated with local failure in 38 primary HNSCC patients treated with chemoradiotherapy or radiotherapy. Vandecaveye et al. \[[@CR28]\] compared the change in ADC between before and 3 weeks after CRT (ΔADC) in 29 HNSCC patients and found that the negative predictive value of ΔADC in terms of tumor response for the primary lesion was 100%, and diffusion-weighted imaging (DWI) was better than anatomical imaging in predicting tumor response. Jacobs et al. \[[@CR29]\] also found that the ΔADC during chemoradiotherapy and 4 weeks post-chemoradiotherapy were the best predictive parameters for pathological good response. Ceulemans et al. \[[@CR30]\] investigated the role of fluorodeoxy glucose positron emission tomography PET/CT during radiotherapy (47 Gy) and 4 months after radiotherapy in 40 HNSCC patients and found that PET/CT at both times had a high specificity and positive predictive value for the evaluation of tumor response, suggesting that it might be used as an indicator for avoiding unnecessary salvage surgery in patients with CR, although PET/CT at 4 months after radiotherapy had the strongest predictive power. Hur et al. \[[@CR31]\] reported a biomarker-based scoring system for predicting tumor response after preoperative chemoradiotherapy in rectal cancer. They found that the mRNA expression levels of four biomarkers (p53, p21, Ki67, and CD133) significantly correlated with tumor regression grade and pathologic complete response. Radiogenomics, which links different imaging features with diverse genomic events, is a new and exciting field within radiology, and imaging genomic linkages can help in monitoring treatment response. This method now is widely investigated in many types of tumors such as brain tumor, rectal cancer, and head and neck cancer \[[@CR32], [@CR33]\].

In summary, for locally advanced HNSCC, a multidisciplinary treatment modality was the mainstay treatment choice. Achievement of pCR after preoperative treatment is associated with good treatment outcomes. At present, induction chemotherapy followed by concurrent chemoradiotherapy or concurrent chemoradiotherapy, with surgery as salvage therapy, is used with increasing frequency in the treatment of locally advanced HNSCC. Determining how to assess the tumor response accurately after preoperative treatment is very important, and for patients who achieved pCR, surgery may be avoidable, which improves organ function preservation. Moreover, it is reasonable to expect that the tumor response after preoperative treatment will help to predict outcome even more accurately when combined with clinical characteristics based on functional imaging, biomarkers, and genomics.

Supplementary information
=========================

 {#Sec13}

**Additional file 1: Table S1.** Multivariate analysis for DMFS and PFS.
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